-
AMPK Links Mitophagy and Inflammation in Diabetic PDL
2026-09-26
This study examines how AMPK regulates PINK1/Parkin-associated mitophagy and NLRP3-linked inflammation in periodontal ligament fibroblasts exposed to mechanical loading, including under high-glucose conditions. Its in vivo and in vitro findings suggest that AMPK activation can support mitochondrial turnover and weaken proinflammatory signaling, while leaving important questions about model-specific mechanisms and experimental parameters for future work.
-
Protease Inhibitor Cocktail: EDTA-Free Workflow
2026-09-26
This EDTA-free cocktail helps limit proteolysis during protein extraction and downstream sample handling while avoiding EDTA in workflows sensitive to divalent cations. Use it at the specified dilution for compatible applications; assess DMSO and inhibitor compatibility before enzyme assays, and do not rely on it for metalloprotease inhibition.
-
FAISL Stabilizes FAK to Drive TNBC Progression
2026-09-25
A 2024 study identifies the long non-coding RNA FAISL as a protein-level stabilizer of FAK in triple-negative breast cancer, acting by preventing calpain-2-mediated FAK cleavage. The findings connect RNA–protein interaction, focal-adhesion biology, and tumor progression, while suggesting that FAISL-targeted delivery merits further preclinical investigation.
-
Dehydroabietic Acid in Metabolic Research
2026-09-25
Use Dehydroabietic acid to probe PPAR-linked metabolic responses, then pair receptor-level readouts with lipid and insulin-response assays for a more complete picture. A separate adipocyte-targeted CRISPRi study offers a useful comparison point—not evidence that this compound silences Fabp4—and helps researchers design complementary experiments.
-
Anti Reverse Cap Analog in mRNA Workflows
2026-09-24
Learn how ARCA cap chemistry can improve translation in synthetic mRNA workflows, from in vitro transcription through expression testing. A stroke mRNA nanoparticle study illustrates why transcript quality and targeted delivery are separate, complementary parts of a therapeutic strategy.
-
Nigericin Sodium Salt: Practical Workflow Guide
2026-09-24
Nigericin sodium salt is a potassium ionophore for experimentally perturbing K+/H+ exchange, ion gradients, and cytoplasmic pH in membrane-based assays. Use it for controlled research workflows—not as a treatment or diagnostic reagent—and validate dose, exposure, and ionic conditions in each model.
-
HABA for Avidin–Biotin Surface Analysis
2026-09-23
HABA, or 4-hydroxyazobenzene-2-carboxylic acid, is a chromogenic ligand for absorbance-based analysis of avidin–biotin and streptavidin–biotin interactions. Its principal value in PLGA research is measuring functionally accessible biotin on particle surfaces, not total ligand loading, cartilage penetration, drug release, or corticosteroid stability.
-
CB-839 (Telaglenastat) in MYCN Neuroblastoma
2026-09-23
CB-839 (Telaglenastat) provides a direct pharmacological test of GLS1 dependence downstream of PRMT5-regulated splicing in MYCN-amplified neuroblastoma. This article shows how to use glutaminolysis inhibition assays to separate metabolic vulnerability from upstream epitranscriptomic effects.
-
Lysis Buffer for Reliable Mouse Genotyping
2026-09-22
Learn how lysis buffer design influences genomic DNA release from mouse tail samples and downstream genetic analysis. This article connects pre-analytical genotyping quality with transcriptomic research decisions while clarifying the practical role of APExBIO H1002.
-
2-Thio-dCTP for Reproducible DNA Assays
2026-09-21
This scenario-based guide explains where 2-Thio-dCTP, SKU B8104, can strengthen mechanistic DNA assays without being mistaken for a direct cell-viability reagent. It covers polymerase compatibility, handling, interpretation of proliferation and cytotoxicity data, and practical vendor-selection criteria.
-
Canagliflozin and Proximal Tubule Mitochondria
2026-09-21
The 2025 reference study shows that Canagliflozin improves mitochondrial structure and bioenergetics in proximal tubular cells from hypertensive–diabetic mice, with stronger functional effects in males. Its findings support mitochondrial remodeling as a potential component of SGLT2 inhibitor-associated kidney protection beyond glucose lowering alone.
-
Metoprolol Tartrate: β1 Research Workflow
2026-09-20
Metoprolol Tartrate enables selective β1-adrenergic receptor inhibition in cardiomyocyte, hypertension, arrhythmia, and heart failure model studies. Its value extends to transplant research, where recent evidence distinguishes β1-selective blockade from the impaired hematopoietic regeneration associated with nonselective β-blockers.
-
Perphenazine: From D2 Antagonism to Cell-State Biology
2026-09-19
Perphenazine is a dopamine D2 receptor antagonist whose research value extends from schizophrenia research to mitochondrial and host-cell phenotypes. This article presents an assay-centered framework for separating receptor pharmacology, mitochondria-mediated cell death induction, and macrophage antibacterial responses.
-
Atorvastatin: From Mevalonate to Ferroptosis
2026-09-19
Atorvastatin is an HMG-CoA reductase inhibitor with applications spanning cholesterol metabolism research, vascular biology, and emerging ferroptosis studies. This article explains how to interpret its pathway effects and translate the latest hepatocellular carcinoma findings into better assay decisions.
-
EMD638683: A Selective SGK1 Inhibitor
2026-09-18
EMD638683 is a selective SGK1 inhibitor that also targets SGK2 and SGK3 and suppresses NDRG1 phosphorylation. Research findings support its use as a mechanistic probe in endothelial stiffness, hypertension, tumor, and cell-survival studies, but not as a clinical treatment.